TNF and psoriasis: Antibodies that inhibit the tumor necrosis factor (TNF), the interleukin (IL) ‐17, the IL‐23 and the IL‐12/IL‐23 axes have been proven effective in inducing primary endpoints in randomized controlled trials on psoriasis.